Navigation Links
ALVESCO(R) Gains FDA Approval for the U.S. Market
Date:1/16/2008

ALVESCO(R) (ciclesonide) Inhalation Aerosol Approved by FDA for the Maintenance and Prophylactic Treatment of Asthma in Patients 12 years of

Age and Older

ALVESCO(R) Will be Commercialised by U.S. Partner

ZURICH, Switzerland, January 16 /PRNewswire/ -- Nycomed announced today that the Food and Drug Administration (FDA) approved ALVESCO(R) (ciclesonide) Inhalation Aerosol in the United States for the maintenance treatment of asthma and as prophylactic therapy in adult and adolescent patients aged 12 years and older. ALVESCO(R) is an inhaled corticosteroid with novel release and distribution properties. Commercialisation and marketing of ALVESCO(R) will be achieved through a U.S. commercial partner.

The decision of the FDA allows the product to be sold in the largest pharmaceutical market in the world, where it is patent protected until 2017. Nycomed is in active negotiations with possible marketing partners for the commercialisation of ALVESCO(R) in the United States. The outlicensing strategy in the U.S. is consistent with Nycomed's direction to seek marketing and commercialisation partnerships for the Nycomed's assets in the U.S. market.

"The approval of ALVESCO(R) provides a new and effective treatment option to help patients control their asthma and improve their quality of life, and will be an important treatment option for physicians," said Myron Zitt, MD, chief of allergy and immunology at the Queens Long Island Medical Group in Babylon, N.Y., and clinical associate professor of medicine at the State University of New York, Stony Brook, School of Medicine.

"We are very much looking forward to serving patients in the United States with this innovative drug and build upon the experience we already have gained with ALVESCO(R). This approval certainly adds to the respiratory area, which is a key segment for Nycomed to grow", comments Dick Soderberg, Executive Vice President of Int
'/>"/>

SOURCE Nycomed International Management GmbH
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Shareholder Class Action Filed Against GPC Biotech AG by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
2. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
3. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
4. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
5. Shareholder Class Action Filed Against LCA-Vision, Inc. by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
6. N-Viro International Corporation Announces Dismissal of Lawsuit Against It
7. Hospitals Adopt STERIS Advanced Room Sterilization Technology in the Fight Against Superbugs
8. Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge
9. Daval International Limited Gains Approval for Phase IIB Trial of AIMSPRO(R)
10. NOLabs AB Achieves Break-Through in Fight Against MRSA-Bacteria
11. Cystic Fibrosis: License Agreement Boosts Development of Therapy Against Lung Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... Noblis, Inc., ... announced in a paper published this week in the scientific journal Viruses ( ... diagnostic techniques currently used to detect the Ebola virus. Noblis worked with the ...
(Date:6/30/2015)... SAN DIEGO , June 30, 2015 /PRNewswire/ ... Continuing Education in Biosciences (CCE/Bio) and UC San ... microbial fermentation, to be held Aug.  12 – ... agenda ).  This three-day workshop provides an intense ... in industrial biotechnology, and is well-suited to biologists, ...
(Date:6/30/2015)... NEW YORK , June 30, 2015  The Dr. ... is now offering a full suite of new ... who,ve had a biopsy, for diagnosing prostate cancer. ... a range of genetic tests for assessing the risk and ... "We,re very excited to now offer these ...
(Date:6/30/2015)... ... June 30, 2015 , ... Cannavoices ... “Cannavoices,” an unprecedented digital video and broadcast initiative. Produced by filmmakers, the multi-platform ... collection of legal medical cannabis stories ever assembled. , Cannavoices profiles Advocates, ...
Breaking Biology Technology:Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 2Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 3Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 4UC San Diego Extension to Offer Third Annual Microbial Fermentation Workshop 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 3New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 4New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 5Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3
... CHENGDU, China, Sept. 17 /PRNewswire-Asia-FirstCall/ -- Tianyin,Pharmaceutical, ... and supplier of,modernized traditional Chinese medicine (,TCM,) based in ... call to discuss its fiscal,2009 fourth quarter and full ... 2009. , Interested parties may ...
... SOUTH SAN FRANCISCO, Calif., Sept. 17 Rigel Pharmaceuticals, Inc. (Nasdaq: ... public offering of 13,000,000 shares of its common stock at a ... shares are being offered by Rigel. The underwriters have an option ... if any. The offering is expected to close on September 22, ...
... , , , ... the start of enrollment for a phase 2 study comparing its proprietary ... FDA-approved twice-daily injection form of exenatide. Building upon the successful completion ... this year, the phase 2 study is intended to evaluate the doses ...
Cached Biology Technology:Tianyin Pharmaceutical Co., Inc. to Host Fiscal 2009 Earnings Conference Call on Thursday, September 24, 2009 at 10:30 a.m. ET 2Rigel Announces Pricing of Public Offering of 13,000,000 Shares of Common Stock 2Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes 2Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes 3
(Date:6/18/2015)... , June 18, 2015 This report analyzes ... by the following Product Segments, which includes Immunoassay Analyzers ... Immunoassay Systems, Radio Immunoassay Systems, and Nephelometric Immunoassay Systems. ... Canada , Japan ... , Latin America , and ...
(Date:6/17/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... that Xiaomi, one of the world,s largest mobile ... ® family of capacitive touchscreen solutions and ... for its latest smartphones, the Xiaomi Mi Note ... in-cell display solutions and DDICs in discrete display ...
(Date:6/16/2015)... June 16, 2015 Fingerprint Cards has ... sensors in the company,s portfolio from one of its module ... to mainly take place during the third quarter 2015. The ... Asia . Jörgen Lantto, CEO of FPC, ... the   growing interest from smartphone OEMs in integrating touch ...
Breaking Biology News(10 mins):Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2
... Southern Oscillation (ENSO), altering the cycles of El Nio and ... Australia and many other Pacific-rim countries., New research published in ... revealed how the ENSO cycle has changed over the past ... impact on the strength and timing of El Nio events., ...
... Scientists have discovered where plants build tannins, complex chemicals ... is the tannosome, a newly discovered organelle that is ... are made from cells; whether they are single-celled organisms ... which millions of cells make up the body of ...
... made a basic science discovery that advances the understanding ... damaged it ultimately leads to cancer. , Faculty of ... published their findings in the peer-reviewed journal, Structure ... thought two key proteins involved in DNA repair operated ...
Cached Biology News:Global warming could change strength of El Niño 2New cell component important to tea and wine-making 2Discovery about DNA repair could lead to improved cancer treatments 2
1, 2 or 8 PreMixes are included as part of the FailSafe™ PCR System....
activating transcription factor 4 (tax-responsive enhancer element B67),...
The Hybrid Hunter Yeast Two-Hybrid System uses the activation of reporter genes to indicate positive protein-protein interactions. Two reporters are used an auxotrophic marker and lacZ....
Request Info...
Biology Products: